Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory and fibrotic pathological condition with undefined effective therapies and a poor prognosis, partly due to the lack of specific and effective therapies. Galectin 3 (Gal-3), a pro-fibrotic ß-galactoside binding lectin, was upregulated in the early stages of the pathology, suggesting that it may be considered a marker of active fibrosis. In the present in vitro study, we use Hylach®, a lactose-modified hyaluronic acid able to bind Gal-3, to prevent the activation of lung myofibroblast and the consequent excessive ECM protein cell expression. Primary human pulmonary fibroblasts obtained from normal and IPF subjects activated with TGF-β were used, and changes in cell viability, fibrotic components, and pro-inflammatory mediator expression at both gene and protein levels were analyzed. Hylach compounds with a lactosylation degree of about 10% and 30% (Hylach1 and Hylach 2), administrated to TGF-β—stimulated lung fibroblast cultures, significantly downregulated α-smooth muscle actin (α-SMA) gene expression and decreased collagen type I, collagen type III, elastin, fibronectin gene and protein expression to near baseline values. This anti-fibrotic activity is accompanied by a strong anti-inflammatory effect and by a downregulation of the gene expression of Smad2 for both Hylachs in comparison to the native HA. In conclusion, the Gal-3 binding molecules Hylachs attenuated inflammation and TGF-β—induced over-expression of α-SMA and ECM protein expression by primary human lung fibroblasts, providing a new direction for the treatment of pulmonary fibrotic diseases.
Hyaluronic acid (HA) is a natural and biocompatible polysaccharide which is able to interact with CD44 receptors to regulate inflammation, fibrosis and tissue reconstruction. It is also a suitable chemical scaffold for drug-delivery to be functionalized with pharmacophore and/or vectorizable groups. The derivatisation of HA can be achieved to varying extents by reacting 1-amino-1-deoxy-lactitol, via the carboxyl group to form amide linkages, giving rise to a grafted polymer named HYLACH®. This retains the broad properties of HA, while coupling its intrinsic properties to those of the substituents, with the crucial advantage that it is more resistant to enzymatic degradation. As in most HA grafted polymers, the detailed conformational effects of such substitutions, while crucial in the design or optimization of drug-delivery systems, remain unknown. Here, the conformational, size, secondary structure, and hydrogen bond network of lactosylated HA derivatives are evaluated employing multiple independent molecular dynamics simulations, that reveal subtle, but nevertheless, significant changes in the HA scaffold, underlining the primary role of the density of grafting in affecting these properties. This study establishes that the density of grafting remains a key structural variable when designing grafted HA polymers for advanced applications such as drug-delivery or drug-vectorization.